<DOC>
	<DOCNO>NCT00064285</DOCNO>
	<brief_summary>RATIONALE : Imatinib mesylate may stop growth cancer cell block enzymes necessary cancer cell growth . Drugs use chemotherapy flavopiridol use different way stop cancer cell divide stop grow die . Combining imatinib mesylate flavopiridol may kill cancer cell . PURPOSE : This phase I trial study side effect best dose flavopiridol imatinib mesylate treat patient hematologic cancer .</brief_summary>
	<brief_title>Flavopiridol Imatinib Mesylate Treating Patients With Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose recommend phase II dose flavopiridol imatinib mesylate patient Bcr/Abl+ hematological malignancy . - Determine toxic effect regimen patient . - Determine disease-related effect regimen patient . - Determine pharmacokinetics pharmacodynamics regimen patient . - Correlate response regimen mechanisms imatinib mesylate resistance patient previously treat imatinib mesylate . OUTLINE : This dose-escalation , multicenter study . Patients stratify accord percentage blast peripheral blood bone marrow ( le 15 % v least 15 % ) recent myelosupressive treatment ( vs yes ) . Patients receive oral imatinib mesylate daily flavopiridol IV 1 hour day 2 , 9 , 16 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos imatinib mesylate flavopiridol maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : A total 6-80 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Alvocidib</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 following : Chronic accelerate phase chronic myelogenous leukemia ( CML ) 1 follow : Hematologic progression prior imatinib mesylate treatment Less complete hematologic response least 3 month prior imatinib mesylate treatment Less major cytogenetic response least 6 month imatinib mesylate treatment ( cytogenetic response document karyotype fluorescence situ hybridization [ FISH ] ) Blastic phase CML* Acute lymphoblastic leukemia* Acute myeloid leukemia* NOTE : *Patients may enrol presentation , remission , upon relapse Bcr/Abl+ bone marrow confirm karyotype FISH No known CNS malignancy PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy Not specify Hematopoietic See Disease Characteristics Hepatic Bilirubin great 1.5 time upper limit normal ( ULN ) AST ALT great 2.5 time ULN ( 5 time ULN hepatic involvement suspect [ stratum 2 ] ) Renal Creatinine great 2 time ULN Cardiovascular No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Other Not pregnant nursing Fertile patient must use effective contraception 3 month study participation No prior allergic reaction attribute compound similar chemical biological composition study agents No concurrent uncontrolled medical illness No ongoing active infection No psychiatric illness social situation would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent filgrastim ( GCSF ) , sargramostim ( GMCSF ) , interleukin2 first course study therapy unless clinically indicate management febrile neutropenia thrombocytopenia Concurrent epoetin alfa allow start study entry remain clinically appropriate Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other See Disease Characteristics Recovered prior therapy No concurrent investigational anticancer agents No concurrent combination antiretroviral therapy HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>untreated adult acute lymphoblastic leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
</DOC>